Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011311
Disease: Dengue Fever
Dengue Fever
0.100 Biomarker disease BEFREE Purified fusion proteins induced serotype-specific neutralizing antibodies without cross-reaction against other serotypes and arboviruses after mouse immunization. hydrophobin-fused domain III of dengue envelope protein could be a promising strategy for easy and low-cost production of components of a tetravalent sub-unit vaccine against dengue. 31828570 2020
CUI: C0011311
Disease: Dengue Fever
Dengue Fever
0.100 Biomarker disease BEFREE A star-shaped DNA architecture, carrying five molecular beacon-like motifs, was constructed to display ten dengue envelope protein domain III (ED3)-targeting aptamers into a two-dimensional pattern precisely matching the spatial arrangement of ED3 clusters on the dengue (DENV) viral surface. 31767992 2020
CUI: C0042769
Disease: Virus Diseases
Virus Diseases
0.100 GeneticVariation group BEFREE Efficient engagement with the envelope glycoprotein membrane-proximal external region (MPER) results in robust blocking of viral infection by a class of broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV). 31787208 2020
Human immunodeficiency virus (HIV) II infection category B1
0.100 Biomarker disease BEFREE Attachment of envelope glycoprotein gp120 to the host cell receptor CD4 is the first step during the human immunodeficiency virus-1 (HIV-1) entry into the host cells that makes it a promising target for drug design. 31792886 2020
Human immunodeficiency virus (HIV) II infection category B1
0.100 Biomarker disease BEFREE Efficient engagement with the envelope glycoprotein membrane-proximal external region (MPER) results in robust blocking of viral infection by a class of broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV). 31787208 2020
Human immunodeficiency virus (HIV) II infection category B1
0.100 GeneticVariation disease BEFREE The human immunodeficiency virus-1 (HIV-1) envelope protein gp120 is the major contributor to the pathogenesis of HIV-associated neurocognitive disorder (HAND). 31320730 2020
CUI: C0011311
Disease: Dengue Fever
Dengue Fever
0.100 Biomarker disease BEFREE Here, the consensus dengue virus envelope protein domain III fused to hydrophobin I of Trichoderma reesei was expressed in Pichia pastoris cultures and an in situ product removal by an ATPS using a non-ionic detergent, (Triton X-114) was performed. 30240632 2019
CUI: C0011311
Disease: Dengue Fever
Dengue Fever
0.100 Biomarker disease BEFREE In this study, we focused on the Dengue viral envelope protein (E); computational analyses ranging from extensive Molecular Dynamics (MD) simulations and energy-decomposition-based prediction of potentially immunoreactive regions identified putative epitope sequences. 31003530 2019
CUI: C0011311
Disease: Dengue Fever
Dengue Fever
0.100 GeneticVariation disease BEFREE In this study, two highly conserved regions of dengue envelope protein were identified and an scFv was constructed against it. 30629625 2019
CUI: C0011311
Disease: Dengue Fever
Dengue Fever
0.100 Biomarker disease BEFREE Here, we investigated four types of recombinant envelope protein domain III (DV-rED III) derived from four dengue virus (DENV) serotypes for diagnostic potential in detecting IgM in acute phase (mainly 2-3 days after onset of fever). 31311082 2019
CUI: C0011311
Disease: Dengue Fever
Dengue Fever
0.100 Biomarker disease BEFREE The virtual approach was based on generating different docking cycles of tetra, penta, hexa, and heptapeptide libraries by maximizing the discrimination between the amino acid motif in the ZIKV and dengue virus (DENV) envelope protein glycosylation site. 31533374 2019
CUI: C0011311
Disease: Dengue Fever
Dengue Fever
0.100 Biomarker disease BEFREE Zika (ZIKV) and dengue (DENV) virus infections elicit a robust but cross-reactive antibody response against the viral envelope protein, while antibody responses against non-structural proteins (NS) are more virus specific. 30902827 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker disease BEFREE We have developed a fully human, second-generation CAR directed against the envelope protein of hepatitis B virus on the surface of infected cells (S-CAR). 30852138 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker disease BEFREE Structure-Guided Approach to Identify Potential Inhibitors of Large Envelope Protein to Prevent Hepatitis B Virus Infection. 31772697 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 GeneticVariation disease BEFREE Here we show that a viral membrane protein, the duck hepatitis B virus (DHBV) large envelope protein (DHBs L), produced by WG-CFPS, is phosphorylated upon translation at the same sites as DHBs L produced during DHBV infection of primary hepatocytes. 31850370 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker disease BEFREE Moreover, the aa 158 sequence determined attachment of the HBV envelope protein to the host cell, demonstrating the mechanism whereby HBV infection would create positive selection at this NTCP residue. 30541857 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker disease BEFREE Here, we modified synthetic lipid-based nanoparticles with targeting peptides derived from the hepatitis B virus large envelope protein (HBVpreS) to specifically target the sodium-taurocholate cotransporting polypeptide (NTCP; <i>SLC10A1</i>) on the sinusoidal membrane of hepatocytes. 31333191 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker disease BEFREE A novel T-cell epitope in the transmembrane region of the hepatitis B virus envelope protein responds upon dendritic cell expansion. 30415392 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker disease BEFREE This is the first report on the mechanisms of HBV envelope protein transport among the organelles, and the results provide important insights into the therapeutic control of HBV infection. 31118260 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE We used long-read, deep-sequenced data of full-length HCV envelope glycoprotein, longitudinally sampled from acute to chronic HCV infection to investigate the underlying viral population and evolutionary dynamics. 30602023 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE In the present study, we constructed genetic vaccines based on novel recombinant adeno‑associated viral (rAAV) vectors (AAV2/8 or AAV2/rh32.33) that express the envelope glycoprotein E2 from the HCV genotype 1b. 30569131 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Our phase I study with recombinant HCV E1/E2 envelope glycoprotein (EnvGPs) as a candidate vaccine did not induce a strong immune response in volunteers. 29443378 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE Overall, statistically significant associations were found between HCV quasispecies diversity, selective pressure exerted on the HCV E2 envelope protein, and neutralizing activity of maternal immunoglobulins. 30365007 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE Assembly of infectious hepatitis C virus (HCV) particles is known to involve host lipoproteins, giving rise to unique lipo-viro-particles (LVPs), but proteome studies now suggest that additional cellular proteins are associated with HCV virions or other particles containing the viral envelope glycoprotein E2. 30880226 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE NS2 also promotes HCV particle assembly by recruiting envelope protein 2 (E2) to the virus assembly sites located at the detergent-resistant membranes (DRM). 31597774 2019